
What is claimed is:

1. A compound of Formula (I):



(I),

or a pharmaceutically acceptable salt or solvate thereof; wherein:

R is -CH_3, -CH_2D, -CHD_2, or -CD_3;

R^2 is hydrogen, –C(O)NHR^5, –C(O)OR^5, –C(O)(linear or branched alkyl), or –C(O)(linear or branched alkenyl);

R^3 is -C(O)OR^6;

R^4 is halogen, -OH, -OR^5, oxo, -NH_2, -NHR^5, -N(R^5)$_2$, -NO_2, -CF_3, –C_1-C_6 alkyl, or –C_1-C_6 haloalkyl;

R^5 is linear or branched alkyl;

R^6 and R^1 together is an alkylene group or an alkenylene group which with the atoms which they are each bonded to, forms a 12 to 25 membered ring, wherein 1, 2, 3, or 4 –CH_2– units making up the alkylene group or the alkenylene group is optionally replaced with a heteroatom selected from –O–, –S–, or –N–, provided that no adjacent –CH_2– is replaced; wherein the alkylene group or the alkenylene group is optionally substituted with one or more R^4; and

wherein, two R^4 on the same or adjacent carbon can form a 3 to 6 membered fused or spiro cycloalkyl ring or a 3 to 6 membered fused or spiro heterocyclic ring.

2. The compound of claim 1, wherein:

a) R is -CH_3 or -CD_3; or


b) R^2 is hydrogen.

3. The compound of claim 1, wherein R^6 and R^1 together is an alkylene group or an alkenylene group which with the atoms which they are each bonded to, forms a 13 to 24 membered ring, wherein 1, 2, 3, or 4 –CH_2– units making up the alkylene group or the alkenylene group is optionally replaced with a heteroatom selected from –O–, –S–, or –N–,

provided that no adjacent –CH_2– is replaced; wherein the alkylene group or the alkenylene group is optionally substituted with one or more R^4.

4. The compound of claim 1, wherein the compound is a pharmaceutically acceptable salt selected from sodium salt, potassium salt, lithium salt, Na_2PO_4H salt, hydrochloric acid salt, formic acid salt, trifluoroacetic acid salt, acetic acid salt or trichloroacetic acid/2 lithium salt.

5. The compound of claim 1, wherein the compound has the structure of Formula (I-A):



(I-A),

or a pharmaceutically acceptable salt or solvate thereof; wherein:

R is -CH_3, -CH_2D, -CHD_2, or -CD_3;

R^2 is hydrogen, –C(O)NHR^5, –C(O)OR^5, –C(O)(linear or branched alkyl), or –C(O)(linear or branched alkenyl);

R^4 is halogen, -OH, -OR^5, oxo, -NH_2, -NHR^5, -$N(R^5)_2$, -NO_2, -CF_3, –C_1-C_6 alkyl, or –C_1-C_6 haloalkyl;

R^{4a}, R^{4b}, R^{4c}, and R^{4d}, each independently, is H, halogen, -OH, -OR^5, oxo, -NH_2, -NHR^5, -$N(R^5)_2$, -NO_2, -CF_3, –C_1-C_6 alkyl, or –C_1-C_6 haloalkyl;

R^5 is linear or branched alkyl;


R^{6a} and R^1 together is an alkylene group or an alkenylene group which with the atoms which they are each bonded to, forms a 12 to 25 membered ring, wherein 1, 2, 3, or 4 –CH_2– units making up the alkylene group or the alkenylene group is optionally replaced with a heteroatom selected from –O–, –S–, or –N–, provided that no adjacent –CH_2– is replaced; wherein the alkylene group or the alkenylene group is optionally substituted with one or more R^4; and

wherein, R^{4a} and R^{4b} or R^{4c} and R^{4d} together can form a 3 to 6 membered spiro cycloalkyl ring or a 3 to 6 membered spiro heterocyclic ring; or

wherein R^{4b} and R^{4c} together can form a 3 to 6 membered fused cycloalkyl ring or a 3 to 6 membered fused heterocyclic ring.

6. The compound of claim 5, wherein R^{4a} is $–C_1$-C_6 alkyl and R^{4b}, R^{4c}, and R^{4d} are each H.

7. The compound of claim 1, wherein the compound has the structure of Formula (III-A):



(III-A),

or a pharmaceutically acceptable salt or solvate thereof; wherein:

R is $-CH_3$, $-CH_2D$, $-CHD_2$, $-CD_3$;

R^2 is hydrogen, $–C(O)NHR^5$, $–C(O)OR^5$, –C(O)(linear or branched alkyl), or –C(O)(linear or branched alkenyl);

R^5 is H or linear or branched alkyl;

R^{5a} is halogen, $-OH$, $-OR^5$, oxo, $-NH_2$, $-NHR^5$, $-N(R^5)_2$, $-NO_2$, $-CF_3$, $–C_1$-C_6 alkyl, or $–C_1$-C_6 haloalkyl;

wherein, two R^{5a} on the same or adjacent carbon can form a 3 to 6 membered fused or spiro cycloalkyl ring or a 3 to 6 membered fused or spiral heterocyclic ring;

n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11; and

p is 0, 1, 2, 3, 4, 5, 6, 7, or 8.

8. The compound of claim 7, wherein R is $-CH_3$ or $-CD_3$.

























9. The compound of claim 7, wherein R^2 is H.


















10. The compound of claim 7, wherein n is 0, 1, 2, 3, 4, 5, 6, or 7.

11. The compound of claim 7, wherein p is 0, 1, or 2.

12. The compound of claim 7, wherein R^{5a} is $-C_1$-C_6 alkyl.

13. The compound of claim 1, selected from:


;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;


;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;
















;

;

;









;









;


;

;

;

;

;

;

;

;

;

;

;

;

;

; or

;

or a pharmaceutically acceptable salt thereof.

















14. The compound of claim 1, selected from:





















;

;

;

;

;

;

;

;



;

;

;

;

;

;

; or

;

or a pharmaceutically acceptable salt thereof.


15. The compound of claim 1, selected from:



;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;



O
NH.HCOOH
N
H
N
CH3
O
O
;

O
NH.HCl
N
H
N
CH3
O
O
;

O
NH.HCl
N
H
N
CD3
O
O
;

O
NH.HCl
N
H
N
CD3
O
O
;

O
NH(FA0.5)
N
H
N
CD3
O
O
;

O
NH.FA
N
H
N
CD3
O
O
;

O
NH.FA
N
H
N
CD3
O
O
;

O
NH.FA
N
H
N
CH3
O
O
;

NH.FA
HN
N
CD3
O
O
O
;

NH.FA
HN
N
CD3
O
O
O
;

NH.FA
HN
N
CD3
O
O
O
;

O
NH.FA
N
H
N
CD3
O
O
;

O
NH.FA
N
H
N
CD3
O
O
;

O
NH.FA
N
H
N
CD3
O
O
;

O
NH.FA
N
H
N
CD3
O
O
;

O
NH.FA
N
H
N
CD3
O
O
;

O
NH.FA
N
H
N
CD3
O
O
;

O
NH.FA
N
H
N
CD3
O
O
;

O
NH.FA
N
H
N
CD3
O
O
;


O
NH.FA
N
H
N
CD3
O
O
;

O
NH.FA
N
H
N
CD3
O
O
;


O
NH.FA
N
H
N
CD3
O
O
;




;


;


;



;


; or


; wherein FA is formic acid (HCOOH).


16. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.

17. A compound having the structure:




or a pharmaceutically acceptable salt thereof.

18. The compound of claim 17, wherein the compound is a hydrochloric acid salt of




.

19. A compound having the structure:



or a pharmaceutically acceptable salt thereof.

20. The compound of claim 19, wherein the compound is a hydrochloric acid salt of



.